Andrew Cooper
Stock Analyst at Raymond James
(2.27)
# 1,446
Out of 4,413 analysts
105
Total ratings
45.79%
Success rate
-7.09%
Average return
Main Sectors:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Downgrades: Outperform | $68 → $85 | $92.88 | -8.48% | 5 | Feb 20, 2024 | |
| QDEL QuidelOrtho | Downgrades: Outperform | $100 → $76 | $40.55 | +87.42% | 12 | Feb 14, 2024 | |
| HOLX Hologic | Maintains: Outperform | $85 → $88 | $75.77 | +16.14% | 9 | Feb 2, 2024 | |
| RVTY Revvity | Maintains: Outperform | $106 → $127 | $102.47 | +23.94% | 4 | Feb 2, 2024 | |
| TMO Thermo Fisher | Maintains: Outperform | $515 → $605 | $568.72 | +6.38% | 4 | Feb 1, 2024 | |
| DHR Danaher | Maintains: Outperform | $240 → $270 | $246.62 | +9.48% | 5 | Jan 31, 2024 | |
| AVTR Avantor | Maintains: Outperform | $23 → $26 | $24.23 | +7.30% | 11 | Jan 26, 2024 | |
| GH Guardant Health | Upgrades: Outperform | $27 | $18.00 | +50.00% | 2 | Nov 13, 2023 | |
| CDNA CareDx | Upgrades: Outperform | $12 | $7.76 | +54.64% | 12 | Aug 15, 2023 | |
| CTKB Cytek Biosciences | Initiates: Market Perform | n/a | $6.01 | - | 1 | Jul 19, 2023 | |
| AZTA Azenta | Initiates: Market Perform | n/a | $52.46 | - | 1 | Jul 19, 2023 | |
| NEO NeoGenomics | Downgrades: Market Perform | n/a | $13.92 | - | 9 | May 16, 2023 | |
| MYGN Myriad Genetics | Maintains: Outperform | $25 → $27 | $19.57 | +37.97% | 3 | Mar 3, 2023 | |
| EXAS Exact Sciences | Downgrades: Market Perform | n/a | $59.35 | - | 7 | Jan 18, 2023 | |
| VCYT Veracyte | Downgrades: Market Perform | n/a | $19.57 | - | 8 | Jan 18, 2023 | |
| FLGT Fulgent Genetics | Initiates: Outperform | $45 | $20.35 | +121.13% | 1 | Nov 18, 2022 | |
| HAE Haemonetics | Maintains: Outperform | $88 → $100 | $91.95 | +8.75% | 6 | Nov 8, 2022 | |
| OSUR OraSure Technologies | Downgrades: Market Perform | n/a | $5.29 | - | 5 | Sep 22, 2021 |
Natera
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $92.88
Upside: -8.48%
QuidelOrtho
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $40.55
Upside: +87.42%
Hologic
Feb 2, 2024
Maintains: Outperform
Price Target: $85 → $88
Current: $75.77
Upside: +16.14%
Revvity
Feb 2, 2024
Maintains: Outperform
Price Target: $106 → $127
Current: $102.47
Upside: +23.94%
Thermo Fisher
Feb 1, 2024
Maintains: Outperform
Price Target: $515 → $605
Current: $568.72
Upside: +6.38%
Danaher
Jan 31, 2024
Maintains: Outperform
Price Target: $240 → $270
Current: $246.62
Upside: +9.48%
Avantor
Jan 26, 2024
Maintains: Outperform
Price Target: $23 → $26
Current: $24.23
Upside: +7.30%
Guardant Health
Nov 13, 2023
Upgrades: Outperform
Price Target: $27
Current: $18.00
Upside: +50.00%
CareDx
Aug 15, 2023
Upgrades: Outperform
Price Target: $12
Current: $7.76
Upside: +54.64%
Cytek Biosciences
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $6.01
Upside: -
Azenta
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $52.46
Upside: -
NeoGenomics
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $13.92
Upside: -
Myriad Genetics
Mar 3, 2023
Maintains: Outperform
Price Target: $25 → $27
Current: $19.57
Upside: +37.97%
Exact Sciences
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $59.35
Upside: -
Veracyte
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $19.57
Upside: -
Fulgent Genetics
Nov 18, 2022
Initiates: Outperform
Price Target: $45
Current: $20.35
Upside: +121.13%
Haemonetics
Nov 8, 2022
Maintains: Outperform
Price Target: $88 → $100
Current: $91.95
Upside: +8.75%
OraSure Technologies
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $5.29
Upside: -